Create your personal agenda –check the favourite icon
Bronwyn Harris is a pediatric cardiologist who clinically practices part-time at Stanford. She has been working in the digital health space for the past decade with a range of experiences from starting her own company to working at Apple. She is currently Chief Transformation Officer for CareEvolution, a health software company with a one-stop digital research platform. Bronwyn is passionate about using patient-generated health data to empower patients and overall improve clinical care.
David Talby is the Chief Technology Officer at John Snow Labs, helping companies apply artificial intelligence to solve real-world problems in healthcare and life science.
David is the creator of Spark NLP – the world’s most widely used natural language processing library in the enterprise. He has extensive experience building and running web-scale software platforms and teams – in startups, for Microsoft’s Bing in the US and Europe, and to scale Amazon’s financial systems in Seattle and the UK.
David holds a Ph.D. in Computer Science and Master’s degrees in both Computer Science and Business Administration. He was named USA CTO of the Year by the Global 100 Awards and Game Changers Awards in 2022
Timothy has been serving the industry for the last 23 years, his last opportunity was the head of R&D of a medium size publicly traded biopharma. He has published 4 books, including a CIOMS approved Textbook of GPV & E and two textbooks of clinical Immune Oncology in solid and liquid tumors. He has published 69 peer review articles. He has led multiple IND/NDA programs in his career in clinical development. He has authored more than 125 individual medical writing in clinical development verticals including IB, Protocols, clinical overviews, etc. He has served top 20 biopharma's in this area including BMS, Sanofi, and Roche. Tim is a trained medical scientist, with US training in clinical oncology, medical research at NCI and UC San Francisco with a Ph.D in epidemiology. He is an ex- fellow of US FDA office of surveillance.
Create your personal agenda –check the favourite icon
Jennifer Lee is a board of directors, investor, venture partner, and SVP of Clinical Operations at Novita Pharmaceuticals. She is an influential biotech executive, driving the transformation of innovative science into life-saving treatments for over two decades. Therapies she’s steered have culminated in $20 billion in value, seven global regulatory approvals, label changes, multiple inspections, and multi-million dollar exits.
Jennifer is a noted STEM advocate and contributes to the field through multiple board and advisory roles and publications.
Ekaterina is a highly experienced professional in the field of bioinformatics consulting, with over 20 years of expertise in various areas of bioinformatics and systems biology. With a background in biophysics, she completed her Ph.D. thesis in molecular evolution before transitioning her focus to systems biology. Throughout her career, Ekaterina has led teams in academic and commercial settings, specializing in drug discovery, patient subpopulation selection, and precision medicine applications using multi-omics approaches, network and pathway analysis. She has always been actively involved in establishing partnerships with interdisciplinary teams and has made significantcontributions to grant applications and deliveries.
Driven by her passion for translational medicine, Ekaterina co-founded a company dedicated to NGS-based cancer treatment predictions. Working closely with molecular oncologists, bioinformaticians, and systems biologists, the company focused on the application of systems biology to precision medicine, benefiting from seed investmentsand grants.
In addition to her scientific expertise, Ekaterina has played an important role in client- facing activities and business development. She has conducted client needs assessments, explored market opportunities, proposed innovative solutions, and successfully overseen project management across a diverse range of therapy areas, including oncology,neuromuscular, skin, rare, and autoimmune diseases.
Breakthroughs in drug discovery depend on bioinformatics and in silico R&ED. Understanding the conclusions and harnessingthem in target discovery and validation rely on digital literacy, often overlooked yet pivotal. Our session will share insights, struggles, and solutions from our journey to create personalized learning journeys in bioinformatics and in silico R&ED within the line of business, integrating digital advancements into the everyday practice of R&ED, locally and globally. The goal is to prepare everyone for genAI employability, harvest digital skills to democratize understanding of bioinformatics and in silico R&ED within the line of business, and seamlessly integrate these practices within a global setting.
I will explore the critical elements of developing a robust strategy that leverages the power of quantum computing to drive the use of quantum applications in research innovation. This strategy will be centered around identifying compelling use cases where quantum computing can make a significant impact, integrating artificial intelligence to enhance quantum solutions, and fostering a skilled workforce adept in both quantum and AI technologies. I will also emphasize the importance of aligning these efforts with organizational goals to create tangible value. Through real-world examples and a practical roadmap, I aim to demonstrate how a well-crafted quantum application strategy can transform research processes and outcomes, ultimately delivering substantial value to both academic and industrial endeavors.
Revolutionizing patient care: Necrobotics pioneers a healthcare revolution by seamlessly integrating AI and robotics, pushing the boundaries of innovation in patient treatment and diagnostics.
Precision in healthcare procedures: Exploring the dynamic synergy between AI and robotics, enhancing precision in diagnostics, surgeries and overall healthcare delivery for a more effective patient experience.
Navigating ethical considerations: Delving into the ethical considerations surrounding AI-driven necrobotics, emphasizing responsible deployment through the establishment of robust regulatory frameworks.
Collective vision for tomorrow: Necrobotics serves as a collaborative platform, bringing together experts and stakeholders to shape a future where AI and robotics harmonize to redefine and elevate the healthcare landscape.